Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease

Experimental Neurology

Volumn 185, Issue 1, 2004, Pages 63-80

  O'Neill, Kathleen ^a   Chen, Shuhua ^a   Brinton, Roberta Diaz ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Basal forebrain; Beta amyloid; Cerebral cortex; Estrogen agonist; Estrogen antagonist; Hippocampus; Neuroprotection; Neurotrophism; Raloxifene; SERM

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; AMYLOID BETA PROTEIN[25-35]; BIOLOGICAL MARKER; ESTRADIOL; GLUTAMIC ACID; HYDROGEN PEROXIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGING; AGONIST; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN CELL; BRAIN CORTEX; CELL STRUCTURE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG SELECTIVITY; EMBRYO; ESTROGEN ACTIVITY; FETUS; FOREBRAIN; HIPPOCAMPUS; MEMBRANE DAMAGE; MEMORY; NERVE CELL; NERVE FIBER GROWTH; NERVE FIBER REGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RAT;

EID: 0347624528     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.09.005     Document Type: Article

References (58)

1. Akiyama T., Ishida J., Nakagawa S., Ogawara, Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262:1987;5592-5595.
2. Ames B.N., Shigenaga M.K., Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. U. S. A. 90:1993;7915-7922.
3. Baker V.L., Draper M., Paul S., Allerheiligen S., Glant M., Shifren J., Jaffe R.B. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. (see comments) J. Clin. Endocrinol. Metab. 83:1998;6-13.
4. Behl C. Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res. 290:1997;471-480.
5. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 77:1994;817-827.
6. Behl C., Widmann M., Trapp T., Holsboer F. 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem. Biophys. Res. Commun. 216:1995;473-482.
7. Behl C., Skutella T., Lezoualc'h F., Post A., Widmann M., Newton C.J., Holsboer F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol. Pharmacol. 51:1997;535-541.
8. Birge S.J. Hormones and the aging brain. Geriatrics. 53(Suppl. 1):1998;S28-S30.
9. Brinton R.D., Proffitt P., Tran J., Luu R. Equilin, a principal component of the estrogen replacement therapy premarin, increases the growth of cortical neurons via an NMDA receptor-dependent mechanism. Exp. Neurol. 147:1997;211-220.
10. Brinton R.D., Tran J., Profitt P., Kahil M. 17 β-estradiol increases the growth and survival of cultured cortical neurons. Neurochem. Res. 22:1997;1339-1351.
11. Brinton R.D., Chen S., Montoya M., Hsieh D., Minaya J., Kim J., Chu H.-P. The Women's Health Initiative Estrogen Replacement Therapy in neurotrophic and neuroprotective. Neurobiol. Aging. 21:2000;475-496.
12. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758.
13. Cohen F.J., Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas. 34:2000;65-73.
14. Cosman F., Lindsay R. Selective estrogen receptor modulators: clinical spectrum. (Review, 179 refs) Endocr. Rev. 20:1999;418-434.
15. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337:1997;1641-1647.
16. Dodge J.A., Lugar C.W., Cho S., Short L.L., Sato M., Yang N.N., Spangle L.A., Martin M.J., Phillips D.L., Glasebrook A.L., Osborne J.J., Frolik C.A., Bryant H.U. Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J. Steroid Biochem. Mol. Biol. 61:1997;97-106.
17. Foy M.R., Xu J., Xie X., Brinton R.D., Thompson R.F., Berger T.W. 17β-estradiol enhances NMDA receptor-mediated EPSPs and long-term potentiation. J. Neurophysiol. 81:1999;925-928.
18. Genazzani A.R., Bernardi F., Stomati M., Rubino S., Giardina L., Luisi S., Monteleone P., Genazzani A.D., Luisi M., Petraglia F. Raloxifene analog LY 117018 effects on central and peripheral beta-endorphin. Gynecol. Endocrinol. 13:1999;249-258.
19. Goldstein S.R., Scheele W.H., Rajagopalan S.K., Wilkie J.L., Walsh B.W., Parsons A.K. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet. Gynecol. 95:2000;95-103.
20. Grandbois M., Morissette M., Callier S., Di Paolo T. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. NeuroReport. 11:2000;343-346.
21. Green P.S., Gordon K., Simpkins J.W. Phenolic A ring requirement for the neuroprotective effects of steroids. J. Steroid Biochem. Mol. Biol. 63:1997;229-235.
22. Green P.S., Gridley K.E., Simpkins J.W. Nuclear estrogen receptor-independent neuroprotection by estratrienes: a novel interaction with glutathione. Neuroscience. 84:1998;7-10.
23. Katzenellenbogen B.S., Korach K.S. A new actor in the estrogen receptor drama-enter ER-beta. Endocrinology. 138:1997;861-862.
24. Katzenellenbogen B.S., Sun J., Harrington W.R., Ganessunker D., Katzenellenbogen J. Structure-function relationships in estrogen receptors and the characterization of novel selective estrogen receptor modulators with unique pharmacological profiles. Ann. N.Y. Acad. Sci. 949:2001;6-15.
25. Klein R., Berlin L. Benefits and risks of hormone replacement therapy. Pavlik E.J. Estrogens, Progestins and Their Antagonists. Hormones in Health and Disease. 1996;3-50 Birkhäuser, Boston.
26. Levenson A.S., Jordan V.C. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. 58:1998;1872-1875.
27. Mattson M.P. Calcium as sculptor and destroyer of neural circuitry. Exp. Gerontol. 27:1992;29-49.
28. Mattson M.P., Kater S.B. Excitatory and inhibitory neurotransmitters in the generation and degeneration of hippocampal neuroarchitecture. Brain Res. 478:1989;337-348.
29. Mattson M.P., Barger S.W., Cheng B., Lieberburg I., Smith-Swintosky V.L., Rydel R.E. beta-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease. Trends Neurosci. 16:1993;409-414.
30. Mitlak B.H., Cohen F.J. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm. Res. 48:1997;155-163.
31. Nickelsen T., Lufkin E.G., Riggs B.L., Cox D.A., Crook T.H. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology. 24:1999;115-128.
32. Nilsen J., Brinton R.D. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology. 143:2002;205-212.
33. Nilsen J., Brinton R.D. Impact of progestins on estradiol potentiation of the glutamate calcium response. NeuroReport. 13:2002;825-830.
34. Nilsen J., Brinton R.D. Divergent impact of progesterone and medroxyprogesterone acetate (provera) on nuclear mitogen-activated protein kinase signaling. PNAS. 100:2003;10506-10511.
35. Nilsen J., Mor G., Naftolin F. Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells. Menopause. 5:1998;211-216.
36. O'Neill K., Hen S., Kim J., Oji G., Brinton R.D. Effect of the SERM tamoxifen on neuronal outgrowth and survival. Soc. Neurosci. Abstr. 25:1999;815-847.
37. Posner M.I., Petersen S.E., Fox P.T., Raichle M.E. Localization of cognitive operations in the human brain. Science. 240:1988;1627-1631.
38. Purdie D.W., Beardsworth S.A. The selective oestrogen receptor modulation: evolution and clinical applications. Br. J. Clin. Pharmacol. 48:1999;785-792.
39. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., Manson J.E., Gass M.L., Stefanick M.L., Lane D.S., Hays J., Johnson K.C., Coker L.H., Dailey M., Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 289:2003;2663-2672.
40. Rowlands M.G., Budworth J., Jarman M., Hardcastle I.R., McCague R., Gescher A. Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem. Pharmacol. 50:1995;723-726.
41. Sato M., Rippy M.K., Bryant H.U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10:1996;905-912.
42. Sherwin B.B. Estrogen and cognitive aging in women. Trends Pharmacol. Sci. 23:2002;527-534.
43. Shumaker S.A., Legault C., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones B.N. III, Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 289:2003;2651-2662.
44. Singer C.A., Figueroa-Masot X.A., Batchelor R.H., Dorsa D.M. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J. Neurosci. 19:1999;2455-2463.
45. Singh M., Setalo G. Jr., Guan X., Warren M., Toran-Allerand C.D. Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. J. Neurosci. 19:1999;1179-1188.
46. Singh M., Setalo G. Jr., Guan X., Frail D.E., Toran-Allerand C.D. Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-alpha knock-out mice. J. Neurosci. 20:2000;1694-1700.
47. Solodkin A., Van Hoesen G.W. Neuropathology and functional anatomy of Alzheimer's disease: Molecular and Neurobiological foundations. Brioni J.D., Decker M.W. Pharmacological Treatment of Alzheimer's Disease: Molecular and neurobiological foundations. 1997;151-177 Wiley-Liss, New York.
48. Soules M.R., Bremner W.J. The menopause and climacteric: endocrinologic basis and associated symptomatology. (Review, 60 refs) J. Am. Geriatr. Soc. 30:1982;547-561.
49. Trevoux R., De B.J., Castanier M., Nahoul K., Soule J.P., Scholler R. Endometrium and plasma hormone profile in the peri-menopause and post-menopause. Maturitas. 8:1986;309-326.
50. Wijayaratne A.L., Nagel S.C., Paige L.A., Christensen D.J., Norris J.D., Fowlkes D.M., McDonnell D.P. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology. 140:1999;5828-5840.
51. Woolley C.S., McEwen B.S. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J. Neurosci. 14:1994;7680-7687.
52. Woolley C.S., Weiland N.G., McEwen B.S., Schwartzkroin P.A. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J. Neurosci. 17:1997;1848-1859.
53. Wu X., Glinn M.A., Ostrowski N.L., Su Y., Ni B., Cole H.W., Bryant H.U., Paul S.M. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res. 847:1999;98-104.
54. Yaffe K., Sawaya G., Lieberburg I., Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 279:1998;688-695.
55. Yaffe K., Krueger K., Sarkar S., Grady D., Barrett-Connor E., Cox D.A., Nickelsen T. Cognitive function in postmenopausal women treated with raloxifene. N. Engl. J. Med. 344:2001;1207-1213.
56. Yang N.N., Bryant H.U., Hardikar S., Sato M., Galvin R.J., Glasebrook A.L., Termine J.D. Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology. 137:1996;2075-2084.
57. Zandi P.P., Carlson M.C., Plassman B.L., Welsh-Bohmer K.A., Mayer L.S., Steffens D.C., Breitner J.C. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 288:2002;2123-2129.
58. Zhao L., Chen Q., Brinton R. Neuroprotection and neurotrophic efficacy of phytoestrogens in cultured hippocampal neurons. Exp. Biol. Med (Maywood). 227:2002;509-519.